NCT02290431 - Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 16, 2014

Primary Completion Date

December 29, 2017

Study Completion Date

December 25, 2018

Conditions

Relapse/Refractory Multiple Myeloma

Interventions

DRUG

LBH589 (panobinostat)

Panobinostat (PAN) capsules were supplied at dose strengths of 10 mg and 15 mg. and dosed at 20mg during treatment phase 1 (21 days) and treatment phase 2 (42 days)

DRUG

bortezomib

Bortezomib (BTZ) s.c: 1.3 mg/m2 was administered during both treatment phase 1 (21 days) \& treatment phase 2 (42 days).

DRUG

dexamethasone

Dexamethasone (Dex): 20mg tablets taken during both treatment phase 1 (21 days \& treatment phase 2 (42 days)

Trial Locations (20)

467-8602

Novartis Investigative Site, Nagoya

277-8567

Novartis Investigative Site, Kashiwa

790-8524

Novartis Investigative Site, Matsuyama

812-8582

Novartis Investigative Site, Fukuoka

503-8502

Novartis Investigative Site, Ōgaki

371 8511

Novartis Investigative Site, Maebashi

377-0280

Novartis Investigative Site, Shibukawa

650-0047

Novartis Investigative Site, Kobe

311-3193

Novartis Investigative Site, Higashiibaraki-gun

602-8566

Novartis Investigative Site, Kyoto

983 8520

Novartis Investigative Site, Sendai

701-1192

Novartis Investigative Site, Okayama

565 0871

Novartis Investigative Site, Suita

135 8550

Novartis Investigative Site, Koto Ku

150-8935

Novartis Investigative Site, Shibuya City

162 8655

Novartis Investigative Site, Shinjuku Ku

190-0014

Novartis Investigative Site, Tachikawa

030 8553

Novartis Investigative Site, Aomori

951-8566

Novartis Investigative Site, Niigata

770-8503

Novartis Investigative Site, Tokushima